# GOG-0218 & ICON7 (bevacizumab)

Source: https://onco.cc/trials/gog-0218-icon7/  
OnCo record `gog-0218-icon7` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding the blood-vessel blocker bevacizumab to first-line chemotherapy delayed relapse by a few months but did not extend life overall.

## Summary

GOG-0218 (1,873 patients): PFS 14.1 vs 10.3 months with concurrent-plus-maintenance bevacizumab (HR 0.72); no OS benefit (NEJM 2011). ICON7 (1,528): modest PFS gain, with an OS benefit confined to high-risk (stage IV or suboptimally debulked) disease. Bevacizumab became a first-line option, mainly for high-risk patients and as the partner for olaparib in PAOLA-1.

## Fields

- Kind: Trial
- Status: mixed
- Last checked: 2026-09-07
- Registry id: NCT00262847
- Phase: 3
- Setting: Newly diagnosed advanced ovarian cancer: carboplatin-paclitaxel ± bevacizumab with bevacizumab maintenance
- Sponsor: GOG; MRC/ICON
- Enrolled: 3401
- Result: GOG-0218 PFS 14.1 vs 10.3 months (HR 0.72); no OS benefit.
- Outcomes: Progression-free survival (GOG-0218): Bevacizumab throughout 14.1 months vs Chemotherapy alone 10.3 months, HR 0.72

## Sources

- ClinicalTrials.gov NCT00262847: https://clinicaltrials.gov/study/NCT00262847
- GOG-0218, NEJM 2011: https://www.nejm.org/doi/full/10.1056/NEJMoa1104390

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Platinum-sensitive ovarian cancer](https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [ARCAGY-GINECO](https://onco.cc/companies/arcagy-gineco/), [GOG Foundation](https://onco.cc/companies/gog-foundation/), [MRC Clinical Trials Unit at UCL](https://onco.cc/companies/mrc-ctu/)
- people: [Jonathan A. Ledermann](https://onco.cc/people/jonathan-ledermann/)

---
JSON: https://onco.cc/api/v1/entities/gog-0218-icon7.json